General
Preferred name
CAMAZEPAM
Synonyms
Paxor ()
Limpidon ()
Albego ()
P&D ID
PD009485
CAS
36104-80-0
Tags
drug
Drug Status
investigational
experimental
approved
withdrawn
illicit
Max Phase
2.0
Drug indication
Anxiety
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Camazepam has been shown to bind competitively to benzodiazepine receptors in the brain with a relatively low affinity in animal models. This binding of benzodiazepine receptors by camazepam and its active metabolites is responsible for its anticonvulsant effects. Notably, only three metabolites were shown to exert anticonvulsant activity, temazepam, oxazepam, and hydroxy camazepam. ; ; The anxiolytic properties of camazepam are also attributed to their ability to bind benzodiazepine receptors, also known as GABA receptors. When benzodiazepines bind to GABA receptors they increase the efficiency with which the inhibitory neurotransmitter GABA binds.
METABOLISM Metabolized by the liver into more than 10 metabolites, some of which are also active and posses anticonvulsant properties. [3] One active metabolite of note is temazepam which has roughly equal in effectiveness as an anxiolytic, but is less anticonvulsant, sedating, and motor-impairing.; ; Camazepam undergoes enantioselective metabolism by human liver microsomes. [1]
Compound Sets
6
ChEMBL Drugs
CHEMBL1095282
DrugBank
DB01489
DrugCentral
469
DrugCentral Approved Drugs
469
DrugMatrix
Withdrawn 2.0
w222
External IDs
18
Properties
(calculated by RDKit )
Molecular Weight
371.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
3.18
TPSA
62.21
Fraction CSP3
0.21
Chiral centers
1.0
Largest ring
7.0
QED
0.81
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
ATC
N05BA15
Toxicity type
multiple
Source data